ID: ALA2098388

Max Phase: Preclinical

Molecular Formula: C16H10F3N3O2

Molecular Weight: 333.27

Molecule Type: Small molecule

Associated Items:

Representations

Synonyms (2): TCMDC-142574 | GSK817365A
Synonyms from Alternative Forms(2):

    Canonical SMILES:  O=C(Nc1nnc(-c2ccccc2)o1)c1cccc(C(F)(F)F)c1

    Standard InChI:  InChI=1S/C16H10F3N3O2/c17-16(18,19)12-8-4-7-11(9-12)13(23)20-15-22-21-14(24-15)10-5-2-1-3-6-10/h1-9H,(H,20,22,23)

    Standard InChI Key:  KDUQPXMXHNBKCG-UHFFFAOYSA-N

    Associated Targets(Human)

    Adenylate cyclase type VIII 190 Activities

    Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

    Brain adenylate cyclase 1 372 Activities

    Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

    HEK293 82097 Activities

    Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

    Associated Targets(non-human)

    Mycobacterium tuberculosis variant bovis BCG 1626 Activities

    Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

    Molecule Features

    Natural Product: NoOral: NoChemical Probe: NoParenteral: No
    Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
    Chirality: NoAvailability: NoProdrug: No

    Drug Indications

    MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

    Mechanisms of Action

    Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

    Properties

    Molecular Weight: 333.27Molecular Weight (Monoisotopic): 333.0725AlogP: 4.01#Rotatable Bonds: 3
    Polar Surface Area: 68.02Molecular Species: NEUTRALHBA: 4HBD: 1
    #RO5 Violations: 0HBA (Lipinski): 5HBD (Lipinski): 1#RO5 Violations (Lipinski): 0
    CX Acidic pKa: 9.08CX Basic pKa: CX LogP: 3.63CX LogD: 3.62
    Aromatic Rings: 3Heavy Atoms: 24QED Weighted: 0.79Np Likeness Score: -2.00

    References

    1. Ballell, L., Bates, R. H., Young, R. J., Alvarez-Gomez, D., Alvarez-Ruiz, E., Barroso, V., Blanco, D., Crespo, B., Escribano, J., Gonzalez, R., Lozano, S., Huss, S., Santos-Villarejo, A., Martin-Plaza, J. J., Mendoza, A., Rebollo-Lopez, M. J., Remuinan-Blanco, M., Lavandera, J. L., Perez-Herran, E., Gamo-Benito, F. J., Garcia-Bustos, J. F., Barros, D., Castro, J. P. and Cammack, N. GSK Tuberculosis Screening Data,  [10.6019/CHEMBL2095176]
    2. Kaur J, Soto-Velasquez M, Ding Z, Ghanbarpour A, Lill MA, van Rijn RM, Watts VJ, Flaherty DP..  (2019)  Optimization of a 1,3,4-oxadiazole series for inhibition of Ca2+/calmodulin-stimulated activity of adenylyl cyclases 1 and 8 for the treatment of chronic pain.,  162  [PMID:30472604] [10.1016/j.ejmech.2018.11.036]